TB diagnostics in India
From importation and imitation to innovation

August 25 – 26, 2011
Bangalore, India

Host: St. John’s Research Institute, Bangalore, India
Sponsors: McGill University & Global Health Strategies
Technical partners: Bill & Melinda Gates Foundation, Foundation for Innovative New Diagnostics, International Centre for Genetic Engineering and Biotechnology (ICGEB), India & Stop TB Partnership
Industry partners: Association of Biotechnology Led Enterprises (ABLE) & Confederation of Indian Industry (CII)
Media partners: BioSpectrum Asia, Express Pharma & Express Healthcare

Context and rationale
The scale up of DOTS in India is a great public health accomplishment, and yet undiagnosed and poorly managed TB continues to fuel the epidemic. Recognizing these challenges, the Government of India has set an ambitious goal of providing universal access to quality diagnosis and treatment for all TB patients. Innovative tools and delivery systems in both the public and private sectors are critical for reaching this goal. The current in-vitro diagnostics market in India is dominated by imported and generic products, with virtually no innovations. But India has the potential to solve its TB problem with “home-grown” solutions. Just as Indian pharma and biotech companies revolutionized access to high-quality, affordable AIDS drugs and hepatitis vaccines through generic production, Indian diagnostic companies could also become the world’s hub for high-quality generic diagnostics. India also has the potential to lead the world in developing innovative TB diagnostics. For this to happen, Indian industry must move from the import and imitation approach to genuine innovation in both product development as well as delivery. This will require permissive policies, enhanced funding, and collaboration between government, donors, researchers and the private industry. The goal of this conference is to engage these stakeholders to stimulate interest and investments in TB innovations.
TB diagnostics in **India**

From importation and imitation to innovation

**Host:** St. John’s Research Institute, Bangalore, India  
**Sponsors:** McGill University & Global Health Strategies  
**Technical partners:** Bill & Melinda Gates Foundation, Foundation for Innovative New Diagnostics, International Centre for Genetic Engineering and Biotechnology (ICGEB), India & Stop TB Partnership  
**Industry partners:** Association of Biotechnology Led Enterprises (ABLE) & Confederation of Indian Industry (CII)  
**Media partners:** BioSpectrum Asia, Express Pharma & Express Healthcare

---

**Day 1  August 25, 2011**

<table>
<thead>
<tr>
<th>TIME</th>
<th>THEME</th>
<th>KEY SPEAKER(S)</th>
<th>MODERATOR</th>
<th>PANEL DISCUSSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 AM</td>
<td>Registration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Inauguration</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 10:15 AM | Industry – a key partner in TB control | Lucica Ditiu  
**Exec. Secretary, Stop TB Partnership**  
Nachiket Mor  
**Director, IKP Centre for Technologies in Public Health & Chair, Sughavazhvu** | Welcome by: Lawrence D’Souza  
**Director, SINAHS** | Vote of thanks by: K. Srinivasan  
**Dean, SJRI** |
| 10:15 AM | Keynote: TB in India: burden, progress, and needs | KS Sachdeva  
**RNTCP**  
Soumya Swaminathan  
**NIRT** | Madhukar Pai  
**McGill** | KS Sachdeva – **RNTCP**  
Peter Small – **BMGF**  
Lucica Ditiu – **Stop TB Partnership**  
Puneet Dewan – **WHO** |

**TEA BREAK**

<table>
<thead>
<tr>
<th>TIME</th>
<th>THEME</th>
<th>KEY SPEAKER(S)</th>
<th>MODERATOR</th>
<th>PANEL DISCUSSION</th>
</tr>
</thead>
</table>
| 11:30 AM | TB diagnosis in 2011: state of the art | Mark Perkins  
**FIND**  
Ajay Bakshi  
**McKinsey & Company** | Madhukar Pai  
**McGill** | Mark Perkins – **FIND**  
Ajay Bakshi – **McKinsey & Company**  
Chris Dye – **WHO**  
Nachiket Mor – **ICTPH** |

**LUNCH BREAK**

<table>
<thead>
<tr>
<th>TIME</th>
<th>THEME</th>
<th>KEY SPEAKER(S)</th>
<th>MODERATOR</th>
<th>PANEL DISCUSSION</th>
</tr>
</thead>
</table>
| 2:00 PM  | Overcoming barriers to innovations in India | Rishi Krishnan  
**IIM-B** | Anita Goel  
**Nanobiosym** | Rishi Krishnan – **IIM-B**  
Tanjore Balganesh – **AstraZeneca**  
Pradip Desai – **Span Diagnostics**  
Munesh Makhija – **GE Healthcare**  
Vijay Chandru – **Strand Life Sciences** |
| 3:00 PM  | Biotech companies in India: what will get them interested in TB? | Chandrasekhar Nair  
**Bigtec Labs**  
Anu Acharya  
**Ocimum** | Anand Sivaraman – **Remidio**  
Dhananjaya Dendukuri – **Achira Labs**  
Sridhar Ramanathan – **ReaMetrix India**  
Sami Gudzer – **Avestagen**  
Gurmukh Advani – **Transasia** |

**TEA BREAK**

<table>
<thead>
<tr>
<th>TIME</th>
<th>THEME</th>
<th>KEY SPEAKER(S)</th>
<th>MODERATOR</th>
<th>PANEL DISCUSSION</th>
</tr>
</thead>
</table>
| 4:30 PM  | Funding for TB innovations in India | Peter Small  
**BMGF**  
Jay Menon  
**X Prize Foundation** | N Sriram  
**Tulip Group** | Priya Mehta – **BVGH**  
Steve Buchsbaum – **BMGF**  
K Hemachandran – **USAID**  
Shirshendu Mukherjee – **Wellcome**  
Nandita Chopra – **NIH** |

**HIGH TEA**
<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Theme</th>
<th>Key Speaker(s)</th>
<th>Moderator</th>
<th>Panel Discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>TEA BREAK</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>LUNCH BREAK</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>TEA BREAK</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Day 2: August 26, 2011**

**Host:** St. John’s Research Institute, Bangalore, India • **Sponsors:** McGill University & Global Health Strategies • Technical partners: Bill & Melinda Gates Foundation, Foundation for Innovative New Diagnostics, International Centre for Genetic Engineering and Biotechnology (ICGEB), India & Stop TB Partnership • Industry partners: Association of Biotechnology Led Enterprises (ABLE) & Confederation of Indian Industry (CII) • Media partners: BioSpectrum Asia, Express Pharma & Express Healthcare
Anuradha Acharya
Chief Executive Officer Ocimum Biosolutions, Hyderabad
Anu Acharya is the Founder & CEO of Ocimum Biosolutions, a global genomics outsourcing partner for discovery, development and diagnostics. Since founding the company in 2000, she has led the company through three strategic international acquisitions, two capital raises for equity investments and launch of several innovative products and services through its proprietary platform called RaaS (Research as a Service). She currently serves as a governing board member at CSIR and also a governing board member at the National Institute for Biomedical Genomics, and serves on the board of ABLE. Prior to founding Ocimum, she has had rich experience in the Telecom, IT and entrepreneurship arenas. She has trained at institutions such as the Indian Institute of Technology at Kharagpur, India (IIT) and University of Illinois where she has two Post Graduate degrees in Physics and MIS. She was recently named a “Young Global Leader” by the World Economic Forum.
anu@ocimumbio.com

Gurmukh Advani
President – Sales & Marketing, Transasia Biomedicals Ltd, Mumbai
Gurmukh Advani is a medical graduate from Grant Medical College and JJ Group of Hospitals, Mumbai. He went on to do an MBA in marketing and finance and has worked in various industries such as FMCG and financial sector, before entering the healthcare diagnostics domain. He has worked extensively in the imaging, in- vivo and in vitro diagnostics segments. He has held successive positions in GE Medical Systems and Siemens, including being CEO of Siemens Healthcare Diagnostics Ltd. He is currently President – Sales and Marketing at Transasia Biomedicals Ltd. – a leader in the IVD industry in India. He is currently focusing on bringing exciting technologies like Molecular Diagnostics, especially NAAT and PCR under the Transasia banner. His special interests include setting up a world class infrastructure for research on diagnostic products in the fields of TB, HIV, and HPV.
g.advani@transasia.co.in

Ramnik Ahuja
Head, Public Health Confederation of Indian Industry (CII), New Delhi
Ramnik Ahuja is Head- Public Health with the Confederation of Indian Industry. For more than 8 years, she has led the health work at CII. Her profile broadly involves Quick Need Assessment to develop a comprehensive structure of Interventions in Public Health for industry and synergizing their role in implementing public Health programmes. She also continues to spearhead the Global Fund RCC R 4&6 Proj - to set up Corporate ART Centres across the country. She has more than 11 years of experience on core public health issues which include developing strategies, policies & programmes, curriculum – guidelines and conducting operational research. Dr. Ahuja has earlier served as a Senior Resident in Community Medicine in Medical College, Chandigarh and as a Branch Manager, Family Planning Association of India. She has authored a number of articles published in both reputed national and international journals.
ramnik.ahuja@cii.in

Ajay Bakshi
Associate Principal McKinsey & Company, Inc., New Delhi
Ajay Bakshi is an Associate Principal in McKinsey & Company’s New Delhi Office, where he has worked primarily in the areas of healthcare including hospitals, pharmaceutical & medical products, health insurance, and medical technology. Prior to McKinsey, Ajay worked as a neurosurgeon for five years with special interest in minimally invasive neurosurgery and spinal surgery. He was also on the research faculty of Drexel University College of Medicine, Philadelphia, where he performed research on stem cell transplantation and developing novel biomaterials. He received funding as a PI from the NIH and the Nanotechnology Institute. His research has been published in several journals. Ajay has an M.B.B.S. and an M.Ch. in Neurosurgery from the All India Institute of Medical Sciences, New Delhi and has completed the Wharton Management Program from The Wharton School.
Ajay_Bakshi@mckinsey.com
Tanjore Balganesh post graduated from JIPMER, Madras University in Medical Microbiology. His completed his PhD on Drug Resistance in *Vibrio cholerae* from the Indian Institute of Chemical Biology and the degree was awarded by Calcutta University India. He went on for his Post doctorate studies at the Brookhaven National Laboratories, Brookhaven, New York, USA with Dr. Sanford Lacks. Following this stint he worked with Professor Thomas Trautner at Max Plank Institute for Molecular Genetics at West Berlin, Germany. He joined erstwhile Astra in 1987 and is currently VP and Head of Innovative Medicine Science Head, Bangalore at AstraZeneca, Bangalore, India. Since 2000 he has led AZ’s efforts on TB drug discovery. He led the AZ Bangalore towards delivering its first candidate drug for the treatment of TB which has recently successfully completed Phase 1 studies. He has over 25 publications in several high impact journals. He has 5 internationally granted patents to his credit.

Caroline Bogren has been the Manager of the Global Drug Facility (GDF), Stop TB Partnership, WHO, since November 2010.  She graduated LLB  (Hons) from the University of Auckland, New Zealand in 1988 and practiced corporate law for 6 years. Ms Bogren has extensive UN experience, commencing with UN Secretariat and the peace keeping missions in the Former Yugoslavia, Iraq, East Timor and Kosovo. After 7 years with UN Secretariat, Ms Bogren accepted a position in 2000 as Team Leader/Contracts Officer, with UNICEF Supply Division in Copenhagen, Denmark. Ms Bogren was the Chief, Supply & Procurement, UNICEF India Country Office from 2004 to 2008. In 2008, Ms Bogren joined UNOPS in Copenhagen as Deputy Director, Global Services Centre. During 2010 and prior to the assignment with GDF, Ms Bogren worked as a consultant to the Pharmaceutical Management Advisory Services Team, Global Fund.

Steve Buchsbaum received a Ph.D. in Physics from the University of California, San Diego, and a Master of Pacific International Affairs from the Graduate School of International Relations and Pacific Studies. At the Gates foundation, Dr. Buchsbaum is the Deputy Director for Strategy for the Discovery team. In this role he is responsible for supporting the Discovery Team Director in the cross cutting management of the Discovery team’s activity, including the team’s strategy development and the management and coordination of key grant making tools such as the Grand Challenges in Global Health and the Grand Challenges Explorations Initiatives. Previously, he has held positions at the Scripps Institute of Oceanography; the Institute for Nonlinear Science at University of California; the Los Alamos National Laboratory; and MIT’s Draper Laboratory. He has also served in the U.S. State Department as the Science and Tech Officer for South Asia and as a Program Manager in the DARPA.

Vijay Chandru is an alumnus of BITS Pilani where he trained in Electrical Engineering and went on to get a doctorate from MIT. Vijay is an academic and an entrepreneur who was named in the 50 Pioneers of Change by India Today in 2008. His academic career in mathematical sciences has spanned over thirty years as a research scientist and professor at Purdue University, IBM’s TJ Watson Center, Indian Institute of Science, UPenn, Stanford and at MIT. He is a fellow of the national academies of science and engineering in India. He currently serves as Chairman & CEO of Strand LS and as the honorary president of ABLE (the apex body of Indian biotechnology industry). He holds adjunct faculty appointments at the International Centre for Theoretical Studies (TIFR) and the National Institute for Advanced Studies in Bangalore.

Sachin Chaturvedi is a Senior Fellow at the Research and Information System for Developing Countries, a think-tank with the Ministry of External Affairs, Government of India New Delhi. Till recently he was Global Justice Fellow at the MacMillan Center for International Affairs at the Yale University, USA, where he worked on drug prices and IPR related issues. He is an economist with specialization in trade and innovation linkages. He works on key policy issues confronting the developing world, especially BRICS. He is author of two books and has published several research articles in various prestigious journals. He recently published a report on “South-South Cooperation in Health and Pharmaceuticals: Emerging Trends in India-Brazil Collaborations”.

---

**Caroline Bogren**
Manager, Global Drug Facility, Stop TB Partnership Secretariat & World Health Organization

**Steve Buchsbaum**
Deputy Director, Discovery, Bill & Melinda Gates Foundation, Seattle

**Vijay Chandru**
Chairman & CEO, Strand Life Sciences, Bangalore

**Sachin Chaturvedi**
Senior Fellow, Research and Information System For Developing Countries, New Delhi
Virander S. Chauhan
Director, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi

Virander Chauhan obtained his BSc, MSc and PhD in Organic Chemistry from Delhi University. He went on to do a DPhil as a Rhodes Scholar at Oxford University in 1974. After a post-doctoral stint at the University of Georgia, Athens (U.S.A.) he returned to India and taught at St. Stephens College, Indian Institute of Technology, Kanpur and at Delhi University. He joined International Centre for Genetic Engineering and Biotechnology at New Delhi to head the Malaria and Structural Biology research group in 1998 and became the Director of the Institute in 1999, a position he currently holds. His current research interests include malaria immunology and malaria vaccine Development, mechanism of action of anti-malarials and drug development and design. He is actively involved in policy and organizational decisions at the national level.

virander@icgeb.res.in

Nandita Chopra
NIH Representative, HHS Office South Asia U.S. Embassy, New Delhi

Nandita Chopra is currently posted as the National Institutes of Health (NIH) Representative in India. Ms. Chopra has worked at the NIH for over 15 years in various capacities. Most recently, she focused on HIV/AIDS policy at the Division of AIDS (DAIDS). Ms. Chopra has led the USG efforts to develop a 5 year strategic plan for Pre-exposure Prophylaxis research in conjunction with the CDC and USAID. Prior to this, Ms. Chopra was the Project Officer for the Institute of Medicine’s review of HIVNET 012 (study of Nevirapine as Prevention of Mother-to-Child Infection of HIV). Ms. Chopra’s international experience includes serving as technical advisor within the Global AIDS Program in Mozambique. Her past experience includes consulting with The World Bank on a public private partnership to develop hospitals in Turkey and interning with First Lady Hillary Clinton’s office at The White House to develop a domestic health care agenda, while in graduate school.

ChopraN@state.gov

Anand Daniel
Principal, Accel Partners, Bangalore

Anand Daniel is a Principal at Accel Partners, where he focuses on investments in Healthcare/MedTech, Information Technology, and Clean Energy. Before joining Accel, he was with Flybridge Capital Partners in Boston where he focused on early stage investments across a range of industries. He represented Flybridge as an observer on the boards of CHiL Semiconductor, Digital Lumens and Sciformix. Previously, Anand spent several years in key engineering and product management positions at Intel Corporation working on cutting-edge microprocessor products. He also worked for Intel Capital, where he helped formulate the strategy for investments in the Terascale computing ecosystem. Anand holds an MBA from the MIT Sloan School of Management, an MS in Electrical Engineering from Purdue University and a BE in Computer Science from the University of Madras.

anand@accel.com

B R Das
President, Research & Innovation, Super Religare Laboratories Limited, New Delhi

B R Das is the President, Research and Innovation at Super Religare Laboratories Limited, Mumbai. He is also the Mentor of the Molecular Diagnostics and the Clinical Research Services at SRL. He has over 27 years of experience in the field of medical biotechnology as a researcher and professor, and has over 80 publications in international journals. Several Ph.D. and post-doctoral scientists have completed their research work under his guidance. He has been honored with several National and International Awards such as the Best Young Scientist Award by the Indian National Science Academy, ISCA Young Scientist Award, MP Young Scientist Award, KI Memorial Award for promotion of Medicine Research in Japan, PSC Award for the Best Senior Scientist of the State of Orissa. He has also worked as Visiting Professor in Case Western Reserve University Hospital, Cleveland, USA and Kyoto Medical School, Japan.

brdas@srl.in

Dhananjaya Dendukuri
Chief Executive Officer, Achira Labs Pvt. Ltd., Bangalore

Dhananjaya Dendukuri is currently Chief Executive Officer & Co-Founder of Achira Labs, a Bangalore-based start-up that is building a microfluidic platform for point-of-care medical diagnostics. He received his Ph.D. in Chemical Engineering from MIT in 2007 where his thesis work on synthesizing polymeric particles in microfluidic devices received the Senturia Prize as the best dissertation in the area of micro and nanotechnology at MIT in 2008. Prior to that, Dhananjaya obtained a MASC in Chemical Engineering from the University of Toronto in 2002, Dhananjaya also has a B.Tech in Chemical Engineering from the Indian Institute of Technology, Madras. Dhananjaya’s work at Achira was recently recognized through his being named as one of 20 individuals to receive the Massachusetts Institute of Technology’s Technology Review’s prestigious TR35 awards in India.

d.dendukuri@achiralabs.com
Pradip Desai

Pradip Desai is Founder, Chairman and Director of Span Diagnostics. He is a clinical pathologist by training. He established a flourishing private clinical lab in Surat in 1966. He then established a start-up company—Span Diagnostics, in 1976 for indigenous IVD manufacturing based on in-house R&D which has focused on infectious diseases and blood banking reagents. Today, Span with its high quality products and strong marketing & distribution network across India and abroad is emerging as one of the leading diagnostic companies in the world.

pradipk.desai@gmail.com

Puneet Dewan

Puneet Dewan is the medical officer, TB, with the World Health Organization Regional Office for South East Asia. He is a graduate of the University of California, Los Angeles and an Internal Medicine physician from the University of Washington, Seattle. He joined the US Centers for Disease Control as an Epidemic Intelligence Service Officer in 2001 in the Division of TB Elimination. For more than 10 years, he has worked on tuberculosis control from local programme management and clinical care in San Francisco, to technical and policy analysis and advice for Ministries of Health of multiple countries, most notably India. He works with the RNTCP to evaluate and improve the quality and efficacy of TB control services in India.

dewanp@searo.who.int

Lucica Ditiu

A native of Romania, Lucica Ditiu is a physician and researcher who has devoted her career to improving the lives of people living in communities heavily burdened by TB. A 1992 graduate of the University of Medicine and Pharmacy in Bucharest, Dr Ditiu completed specialty training in pulmonology through a joint programme with the Romanian National Institute of Lung Diseases. In 1999, she received a certificate in International Public Health from George Washington University in Washington, DC. Dr Ditiu began a career with WHO in January 2000 as a medical officer for TB in Albania, Kosovo and Macedonia within the disaster and preparedness unit of the WHO European Regional Office. In 2006 she was selected to be a medical officer in the TB unit of the European Regional Office in Copenhagen. In January 2010 Dr Ditiu joined the Stop TB Partnership Secretariat to lead the TB REACH initiative, whose goal is to improve access to TB treatment. In 2011, she was appointed Executive Secretary of the Stop TB Partnership.

ditiul@who.int

Christopher Dye

Christopher Dye is Director of Health Information in the Office of HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases at the WHO. Chris Dye began professional life as an ecologist in the UK, having been awarded a DPhil in zoology from the University of Oxford. After developing an interest in infectious diseases at Imperial College London, he moved to the London School of Hygiene and Tropical Medicine to bring his research closer to public health. He was head of the School’s Vector Biology and Epidemiology Unit until 1996. In 1996, he joined the World Health Organization where he has developed methods for using national surveillance and survey data to study the large-scale dynamics and control of tuberculosis (TB) and other communicable diseases. He is a Visiting Professor of Zoology at the University of Oxford, a member of the Board of Reviewing Editors for Science, and a Fellow of the UK Academy of Medical Sciences.

dyec@who.int

Anita Goel

As Chair and CEO of Nanobiosym Anita Goel is focused on delivering new game-changing technologies to address the greatest unmet needs in global health, energy, and the environment. A Harvard-MIT-trained Physicist-Physician, Dr. Goel is a globally recognized leader in the emerging field of nanobiophysics. Her pioneering contributions to nanotechnology and nanobiophysics have been recognized globally by prestigious honors and awards including multiple awards from US Government agencies such as Defense Advanced Research Projects Agency (DARPA), Department of Defense (DOD), Department of Energy (DOE), and US Defense Threat Reduction Agency (DTRA). She established Nanobiosym Diagnostics to commercialize the Gene-RADAR technology platform to empower people worldwide with portable, rapid and accurate information about their own health. She holds a PhD in Physics from Harvard University, an MD from the Harvard-MIT Joint Division and a BS in Physics with Honors and Distinction from Stanford University of Health Sciences & Technology (HST), and a BS in Physics with Honors and Distinction from Stanford University.

agoel@nanobiosym.com
Gopi Gopalakrishnan
President & CEO, World Health Partners, New Delhi

Gopi Gopalakrishnan is currently the president and chief executive of World Health Partners, an international charity that is mandated to deliver, on scale, health care to rural communities in developing countries. He has over 22 years of experience in setting up large programmes that harness resources in the private sector to address the needs of the poor. He founded and administered for over nine years Janani, one of the world’s largest service delivery initiatives targeting the rural poor in India’s poorest state. The programme has won international acclaim and the Indian government has suggested its replication across the country. He was also Director, International Programs of DKT International in Washington DC with the responsibility to integrate some of the Janani components in programs in other DKT countries. He has been on the board of DKT International and also served as its country director in Vietnam.
gopi@worldhealthpartners.org

Sami Gudzer
Chief Scientist Avestagen, Bangalore

Sami N. Guzder, Chief Scientist for Biopharma and S&I divisions, with over 20 years’ experience in the field of biochemistry, molecular biology and genetics is leading the design and supervision of various research and discovery projects including the development of molecular diagnostics and drug development for various diseases at Avestagen Limited. Dr. Guzder is currently heading The AVESTAGENOME Project™ - a systems biology based study on the Parsi population. As a Research Scientist at the Center for Molecular Science, UTMB – Galveston, Texas, his work focused on dissecting the molecular mechanisms of DNA repair and Transcription in yeast and humans. As a Postdoctoral Fellow at the University of Rochester he gained extensive experience in molecular biology and genetics of enzymes and transcription factors. His Ph.D. work focused on repair of DNA damaged by alkylating agents.
sami@avestagen.com

K Hemachandran
Senior Advisor (TB Care and Control), USAID India

K. Hemachandran is a Senior Advisor (TB Care and Control), with USAID India. He is a public Health Specialist, with over 11 years of experience with Indian TB Program. He currently oversees the USAID India’s portfolio of TB activities. Prior to joining USAID, he worked for the Government of Kerala, European Commission, WHO and GTZ. Hemachandran completed his medical training from Trivandrum Medical College and a MPH from the Sree Chitra Tirunal Institute of Medical Science and Technology.
hchandran@gmail.com

Szymon Jaroslawski
Postdoctoral Fellow, Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore

Szymon Jaroslawski has a PhD in Molecular Biology and a PG in Pharmaceutical Market Access. He then worked in Europe as a consultant to global and start-up level pharma and biotech companies, helping them build creative reimbursability and pricing strategies for products in development. Also, he collaborated with academics and public health care payers in the field of health economics. Since December 2010 he is at the Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore where he does academic research on how entrepreneurship in innovative drug discovery and diagnostics in India can contribute to provision of new and affordable health technologies to developing countries. His focus is all along the product development, from innovation to accessing markets and patients’ access in developing countries. One of his major projects at IBAB was a Root Cause Analysis of the use of serology tests for TB diagnostics in the private sector in India.
szymon@ibab.ac.in

Anula Jayasuriya
Managing Director Evolve India Life Science fund

Anula Jayasuriya is a life science venture capitalist. Anula is the co-founder of the “Evolve India Life Science Fund” (EILSF), a $90 million fund established in 2006 to make investments in pharmaceutical, biotechnology, medical device and related contract service companies based in India. She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Anula received a BA from Harvard summa cum laude, and an MD and PhD from Harvard. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, England. Her prior positions include VP Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation.
anula.jayasuriya@invascent.com
Zeena Johar

President, IKP Centre for Technologies in Public Health (ICTPH), Hyderabad

Zeena Johar obtained her PhD from the Swiss Federal Institute of Technology, ETH – Zurich, in Molecular Modeling and Design, following her Masters in Chemistry with a specialization in Quantum Chemistry from Punjab University. To pursue her passion of translating basic science research towards populations-based applied research, Dr. Johar joined the IKP Trust in 2007. Dr. Johar is one of the founding members of ICTPH, a research institute working towards innovating sustainable, replicable and scalable healthcare delivery models for rural India.

zeena.johar@ictph.org.in

Bobby John

Senior Program Officer, Bill & Melinda Gates Foundation, New Delhi

Bobby John is a Senior Program Officer with the Bill & Melinda Gates Foundation, working on global health advocacy and public affairs. He was previously the president of Global Health Advocates, a global non-profit organization established to advocate for and catalyze the emergence of a social movement against AIDS, TB, malaria and other diseases of poverty. Dr. John originally trained in India as a physician with the Indian Armed Forces Medical College. He opted out of his Army commission and joined a small village hospital near Pune in Maharashtra State in western India. He worked for five years in the village as a combination surgeon and obstetrician. Subsequently, he set up and headed World Vision India’s countrywide AIDS program. In 2002, he joined the Swiss-based Massive Effort Campaign as its Southeast Asia director, and subsequently became its president.

Bobby.John@gatesfoundation.org

Arjun Kalyanpur

Chief Radiologist and CEO Teleradiology Solutions, Bangalore

Arjun Kalyanpur is CEO of Teleradiology Solutions. He completed his medical education at the AIIMS, New Delhi followed by residency in Radiology. In 1992, Dr Kalyanpur moved to the US where he obtained fellowship training in Body Imaging at the Cornell University Medical Center in New York and in Neuroradiology at the Yale University School of Medicine, and also became certified by the American Board of Radiology. He then worked on the Clinical Faculty of Yale University before returning to India in 1999. In 2002 he set up Teleradiology Solutions, a health care IT Company that today provides teleradiologic interpretations to over 100 hospitals in the US, Singapore, and Europe. Through its Telerad Foundation it provides high quality telediagnostics to remote parts of India where there are patients and scanners but no doctor to interpret the images such as for Ramakrishna Mission Hospital, Arunachal Pradesh.

arjun.kalyanpur@telradsol.com

John Kenneth

Head, Division of Infectious Diseases, St. John’s Research Institute, Bangalore

John Kenneth is a medical doctor with a specialization in Clinical Microbiology from the Christian Medical College Hospital Vellore. He has worked in clinical diagnostics for a number of years prior to moving full time into research. He is presently Professor and Head, Division of Infectious Diseases at the St. Johns research Institute, Bangalore. He is involved in several major research initiatives both Indian and overseas (including multicentric studies) and focuses specifically on tuberculosis. His special interest has been in quality systems and he has been trained in several quality standards; he is active as a Lead assessor for the National Accreditation Board for Laboratories in India. His research focus has been in diagnostics and vaccinology; he professes a passion in integrating science in its purest form with ethically practiced medicine.

johnkennet@gmail.com

Nalini Krishnan

Director, Resource group for Education and Advocacy for Community Health (REACH), Chennai

Nalini Krishnan is a MD in Internal medicine with a strong interest and practice in public health. She is one of the founding members of REACH, an organisation which works to bridge the gap between public health programs and the target recipients by advocacy, education, building partnerships and multi sector networks to control TB. Dr Krishnan is on the board of directors of Kasturi and Sons Ltd, The Hindu Group of publications. She administers a comprehensive health centre for employees of The Hindu which is also serves as a PPM referral centre for TB Care for patients in the community and the general public. She is an active member of the Confederation of Indian Industry- southern region which includes 4 states in India and has previously chaired the healthcare and CSR Subcommittees for the same region.

nalinkrishnan@gmail.com
Rishikesha T Krishnan

Professor, Indian Institute of Management, Bangalore

Rishikesha T. Krishnan has been studying the links between strategy and innovation for almost 20 years. He is currently a Professor and Area Chairperson in the Corporate Strategy & Policy Area at the Indian Institute of Management, Bangalore. He completed a 3-year term as Jamuna Raghavan Chair Professor of Entrepreneurship at IIMB in August 2010. Krishnan holds an M.Sc. in Physics from the IIT, Kanpur; and an M.S. in Engineering-Economic Systems from Stanford University. He obtained his doctorate from the IIM, Ahmedabad. Krishnan’s book *From Jugaad to Systematic Innovation: The Challenge for India*, published in February 2010 identified the challenges faced by India in enhancing industrial innovation and proposed an agenda to enhance innovation output.

rish@IIMB.ERNET.IN

Blessina Kumar

TB/HIV Activist, Public Health Consultant, New Delhi

Blessina Kumar a Public Health Consultant, has worked extensively with poorer communities in India and the Sudan. In Sudan, working with the internally displaced people in the camps around Khartoum, she trained young women and men to take care of health within the camps and fought against the practice of female genital mutilation. Working with the Health Board of the Church of North India, Blessi has trained over 1000 pastors on issues of HIV/AIDS and Gender. A motivational trainer, she has also managed Community Health Projects across north India and advocated extensively against female feticide in the state of Punjab. In the past 7 years she has had the opportunity to monitor and/or evaluate projects implemented by NGO’s and FBOs funded by international donors and contributed into the strategic planning processes. Presently she is the elected community representative and the Vice Chair of the Stop TB Partnership Coordinating Board.

blessi.k@gmail.com

Munesh Makhija

Chief Technology Officer – India, GE Healthcare, John F Welch Technology Centre, Bangalore

Munesh Makhija is Chief Technology Officer for GE Healthcare in India leading 1300 engineers and scientists across GE’s medical devices, diagnostic imaging, healthcare information technology and bio-science businesses. In addition to serving global markets, he focuses on developing healthcare products and solutions specifically for India. Munesh has been with GE for 9 years, in technology, product development & business leadership roles. Prior to that he has 10 years of experience the telecommunications industry. He returned to India last year after living in the US for 18 years. He holds Bachelor’s and Master’s degrees in Electrical Engineering and an MBA.

Munesh.Makhija@med.ge.com

Ashok Malik

Independent Columnist, New Delhi

Ashok Malik has been a journalist for 20 years. He is now an independent columnist writing for a variety of newspapers on public policy, including in the health and social sectors. An article he wrote in the *Asian Age/Deccan Chronicle* in 2010, on how the anthrax scare following 9/11 inadvertently spurred diagnostic innovation in the field of tuberculosis, won him a REACH-Lilly MDR-TB Partnership Media Award for excellence in reporting.

malikashok@gmail.com

Jasjit Mangat

Director, Investments, Omidyar Network India

Jasjit brings considerable global investing and operating experience to his role at Omidyar Network. Leading India’s Access to Capital investments, Jasjit primarily invests in property rights and entrepreneurs serving the BoP market. Prior to joining Omidyar Network, Jasjit served as the head of business solutions and set up the India office for OATSystems, an MIT spinoff enterprise software company acquired by Checkpoint (NYSE: CKP). Jasjit worked as an investment consultant for both The Carlyle Group’s Indian venture capital arm as well as U.S.-based Swander Pace. He was a management consultant for Marakon and began his career as a clean-tech R&D engineer for Osmonics, Inc. (acquired by GE Water). Jasjit earned an MBA from the Kellogg School of Management at Northwestern University, a Master of Engineering in chemical engineering from Cornell University, and a Bachelor of Technology from the Indian Institute of Technology, Bombay, where he was a National Talent Scholar.

jmangat@omidyar.com
Chapa Mehra is Director, Global Health Strategies Emerging Economies, New Delhi. He has worked for several years in the areas of health and development. He was a founder trustee of The Humrahi Trust, a nonprofit trust for gay and bisexual men in New Delhi and has worked extensively with vulnerable populations including sex workers, truckers and sexual minorities. Chapal holds a masters in international health from New York University and a masters in Applied Psychology from Jamia Millia Islamia. He is also the author of Policy Landscape and Think Tanks in India, a report that examines the role of think tanks in the policy formation in India and The Story of Aastha, a report on a successful an HIV intervention targeted at sex workers. He has been previously published and continues to research and write on issues such as microfinance, policy processes, HIV and tuberculosis. In a previous life Chapal held senior editorial positions at Penguin, Oxford University Press and Sage Publications.

cmehra@globalhealthstrategies.com

Padma is the first South Asia regional coordinator for SciDev.Net, and is developing the region’s first network of science (including health and environment) reporters, from Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka. At SciDev.Net she combines her work experience as a science correspondent and in development communication. She started her career as a science correspondent at Press Trust of India (PTI), where she reported extensively from conferences and lab visits. From 2000 to 2004, she ran development communication projects on public health issues at the South Asia office of Panos Institute. Padma has also freelanced for All India Radio, New Scientist, Inter Press Service (IPS). She currently contributes from Delhi to Nature Medicine and is a guest blogger for the online environment section of Guardian, UK. She is part of SciDev.Net’ team that won the 2005 Association of British Science Writers award for best web coverage of the Asian tsunami.

padma@scidev.net

Priya Mehta joined BIO Ventures for Global Health in fall 2008 and serves as the Director of Global Markets. Priya is the author of “Global Health Innovators: a collection of case studies” and “Diagnostics Innovation Map: Medical Diagnostics for the Unmet Needs of the Developing World.” Prior to joining BVGH, Priya was a Senior Consultant at Dalberg Global Development Advisors. At Dalberg, Ms. Mehta advised leading multinational corporations, UN agencies, NGOs and other multilateral organizations across several development sectors including health, governance and public sector reform. Before Dalberg, Priya was an Associate Consultant in at Bain and Company, where she advised leading private sector clients on customer segmentation, growth, and market entry strategies. Priya holds a Bachelor’s Degree in Government from Harvard University.

pmehta@bvgh.org

Jaykumar Menon is an award-winning international human rights lawyer, an entrepreneur, a former McKinsey consultant, and an adjunct professor at McGill University. As director of the education and global development group at the X PRIZE Foundation, he is exploring prizes in water, clean energy, hunger, infectious disease, education technology, and other areas. Jaykumar studied at Columbia Law School (J.D.), the Columbia School of International and Public Affairs (M.I.A.), and Brown University (B.A.). As a scholar, he has written articles in leading international human rights law reference books and law journals. As an entrepreneur, he co-founded a venture-funded Internet company with current seven-figure revenues.

jaykumar@xprize.org

Deepam Mishra is CEO of i2india, and Technovate India – a not-profit technology incubator. i2india is amongst the first technology commercialization and investment firms, founded on initial support from Imperial Innovations, Plc, UK, and various leading Indian business and academic leaders, including Tata Sons. Deepam’s current passion is to accelerate the creation of an eco-system in India, for early-stage technology innovation and entrepreneurship. He has over 15 years of experience in founding and managing several technology-driven start-ups. As a former SRI (Stanford Research International, USA) executive, he founded and managed three hi-tech businesses in video security, medical devices and automotive-safety. He holds a B.Tech from IIT Kanpur, an MS from Texas A&M and an MBA from Wharton.

d.mishra@i2india.in
Neeraj Mohan  
Vice President - Market Dynamics & New Initiatives, Clinton Health Access Initiative, New Delhi

Neeraj joined Clinton Health Access Initiative (CHAI) in 2009 and initially led CHAI’s engagements with generic ARV manufacturers and other supply side collaborators. Over past two years, he has expanded the engagement to include MDR-TB drugs, vaccines and low cost diagnostics in Asia. Neeraj has spent nearly 15 years in strategic and operational functions across industries and close to a decade in the pharma industry. He has a breadth of business and management experience across roles in finance, economic advisory, analytics, operations, marketing and strategy. His expertise in regulatory processes for pharmaceutical products coupled with his business experience enables him to engage effectively with manufacturing partners to solve complex access issues. Neeraj has a degree in Accounting as well as an MBA from the Indian Institute of Management, Ahmedabad.

mneeraj@clintonhealthaccess.org

Nachiket Mor  
Chairman, Sughavazhvu Healthcare, Thanjavur & Director, IKP Centre for Technologies in Public Health, Hyderabad

Nachiket Mor is a Yale World Fellow; has a Ph.D. in Economics from the University of Pennsylvania with a specialization in Finance from the Wharton School; an MBA from the Indian Institute of Management, Ahmedabad; and an undergraduate degree in Physics from the Mumbai University. He has worked with ICICI from 1987 to 2007 in a variety of jobs, and was a member of its Board of Directors from 2001 to 2007. From October 2007 to August 2010, he assisted ICICI in setting up a philanthropic foundation, the ICICI Foundation for Inclusive Growth and served as its founding President. He is now a Director on the Board of the IKP Centre for Technologies in Public Health and the Chairman of the Boards of Sughavazhvu Health Care, CARE India, and IFMR Trust and is closely involved in the evolution of these four organizations in India. He is currently also an independent member of a few other Boards including CRISIL, IKP Trust, IKP Centre for Advancement in Agricultural Practice, and the Institute for Financial Management and Research. He is a member of the Expert Group on Universal Health Coverage set up by the Planning Commission.

nachiket@nachiketmor.net

Shirshendu Mukherjee  
Strategic Advisor- R&D Initiative India, Wellcome Trust, UK

Shirshendu Mukherjee, works for the India Initiative of the Wellcome Trust, as Strategic Advisor and is responsible in India for implementing the initiative on R&D for Affordable Healthcare in India, a 30 million pound initiative of the Trust. Previously, he worked for companies like Ranbaxy, JK Drugs and Pharmaceuticals and Becton Dickinson. Later he moved to join, International Centre for Genetic Engineering and Biotechnology (ICGEB) New Delhi, a premier international research organization in field of human health and agriculture related plant biotechnology as Staff Scientist (IPR and Technology Transfer) at the Delhi Centre, where he was responsible for transferring the technologies developed by the Centre to member countries and protecting the intellectual property. Dr. Mukherjee holds a Ph.D. degree in Microbiology, a law degree (LL.B) and a PG Diploma in IPR and International Trade Laws.

S.Mukherjee@wellcome.ac.uk

Chandrasekhar Nair  
Director & CEO, Bigtec Labs, Bangalore

Chandrasekhar Nair is a Chemical Engineering from BITS Pilani. He has worked in Senior Technology Development and Management positions in scientific research. He has extensive experience in developing and managing multi-disciplinary life sciences projects. He is a co-founder of bigtec, an Innovation Driven New Generation Technologies Company. His current interests are in the development of rapid, low cost, high quality MEMS based diagnostic products. He holds a number of Indian and International patents.

bc@bigtec.co.in

Suresh Narayanan  
Group Editor Technology Review India & BioSpectrum Asia, Bangalore

Narayanan Suresh is the Group Editor of BioSpectrum with the rank of a Sr VP. BioSpectrum is India’s first and only Biotechnology business magazine. He has been tracking the growth and strides made by Indian technology sector for 25 years, first for The Times of India and later for CyberMedia Publications. Suresh is also the editor of the Asia edition of BioSpectrum published from Singapore and MIT’s Technology Review India edition. Suresh started his career as The Times of India’s first Science and Technology Correspondent in 1986 and has written extensively on major developments in nuclear, space, energy, agriculture, biotech, pharma and information technology sector. It was his report about the patenting of turmeric by researchers in the US in the Times of India in 1995 which alerted the Indian governments which got it revoked from the US Patent Office after a two-year legal proceedings. He has presented many papers on the issue in the United Nations, UNEP and other institutions. He is a Masters in Physics from University of Hyderabad.

sureshn@cybermedia.co.in
Dinesh Puri is the Founder Chairman and Managing Director of Medived Innovations. MedVed's business model includes offshore contract design and OEM manufacturing for Western medical device companies. Dinesh has successfully started from scratch, scaled up and monetized businesses, turned around a Motorola JV Company and run 3 successful and large Motorola businesses as CEO. As President and CEO of Global Symphony Software, Dinesh played a key role in spinning out this business from Cambridge Technology Partners, scaling up the business to a 1000+ people organization providing Product Engineering Services to software companies like Siebel and Broadvision. He also founded Powertel Boca, a leading Networking Company which was acquired by Citrix Systems Inc., U.S.A. He is a member of the Young President's Organisation having held the position of Bangalore Chapter Chair, is an active speaker at industry forums and CII CEO business delegations.

dpuri@medived.com

Anjali Nayyar is the Senior VP for Global Health Strategies (GHS), Emerging Economies. GHS works globally on research, advocacy and communications on health and cutting edge health technology areas. Anjali has a Master's Degree in Population Studies and underwent training at the Johns Hopkins University on Health Communications. She began her career developing educational tools for kindergarten children and then joined the national magazine 'Parenting' as assistant editor. Equipped with editorial and media relations experience, she looked after the South and East Asia communications and advocacy activities at the Population Council for six years from 1996 to 2002. In 2002, she joined International AIDS Vaccine Initiative (IAVI) as the India Country Director. In 2005, she moved to New York to the IAVI headquarters to take over as the Vice President – Country & Regional Programmes. Prior to joining GHS in 2010, she supported the President of Program for Appropriate Technologies in Health (PATH) in managing the PATH India program.

anayyar@globalhealthstrategies.com

Madhu Pai did his medical training and community medicine residency in India. He then completed his PhD in epidemiology at the University of California, Berkeley, and a postdoc fellowship at the University of California, San Francisco. He is currently a tenured associate professor of epidemiology at McGill University in Montreal. In addition, he is a Consultant for the Bill & Melinda Gates Foundation, and he co-chairs the Stop TB Partnership’s Working Group on New Diagnostics. He also serves as a member of the Stop TB Partnership’s Coordinating Board. Dr Pai is a Honorary Professor at the University of Cape Town, South Africa, and a Professor Extraordinary at Stellenbosch University in S Africa. He has more than 100 publications, and several research grants. He received the 2007 Union Scientific Prize from the International Union Against TB and Lung Disease. In 2011, he received the Canadian Rising Star in Global Health award from Grand Challenges Canada.

madhukar.pai@mcgill.ca

Shreemanta Parida is a physician from India with PhD in Immunology from National Institute of Immunology. Since May 30, 2011 he heads the Vaccine Grand Challenge Program of Dept of Biotechnology of Ministry of Science and Technology. He spent more than two decades in many centres of excellence in Europe such as WHO-Immunology Research Training Centre in Geneva – 1990-1995, University of Giessen, Germany – 1995-1998, Pasteur Institute of Brussels (1999), University of Oxford (1999-2003) and Max Planck Institute for Infection Biology; MPIIB (2006-2010). He is passionate in translating research from the bench to the clinics at the community level to combat global health issues embracing all stakeholders through an interdisciplinary approach. At MPIIB, he was responsible for the Grand Challenges in Global Health Consortium on “Biomarkers of Protective Immunity against TB in the context of HIV/AIDS in Africa” supported by Bill & Melinda Gates Foundation (BMGF) involving 15 institutions. Shreemanta.parida@gmail.com

Mark Perkins is the co-founder and CSO of the Foundation for Innovative New Diagnostics (FIND), a non-profit organization dedicated to the development of diagnostic tests for poverty-related diseases. He has 20 years of experience in diagnostics development and evaluation. He worked in Brazil for 5 years as a Duke faculty co-directing a collaborative center for infectious diseases research. In 1998 he joined the WHO and the following year established a Diagnostics unit within TDR. Since 2001 he has worked in partnership with the biotechnology sector to accelerate the development, evaluation, and implementation of effective and affordable diagnostics. Dr Perkins received his medical degree from the University of Texas Southwestern Medical School in Dallas. He trained in Internal Medicine and Pediatrics at Vanderbilt University, and completed fellowships in Infectious Diseases and Clinical Microbiology at the NIH, Vanderbilt University, and Duke University.

mark.perkins@finddiagnostics.org

Anjali Nayyar
Senior Vice President Global Health Strategies Emerging Economies, New Delhi

Madhukar Pai
Associate Prof McGill Univ; Co-Chair, Stop TB Partnership’s New Diagnostics WG; Consultant, Bill & Melinda Gates Foundation

Shreemanta Parida
CEO, Vaccine Grand Challenge Program, DBT

Mark Perkins
Chief Scientific Officer Foundation for Innovative New Diagnostics (FIND), Geneva

Dinesh Puri
Chairman & Managing Director, Medived Innovations Private Limited, Bangalore
<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajesh Rai</td>
<td>Chief Executive Officer, India Innovation Fund, Bangalore</td>
</tr>
<tr>
<td></td>
<td>Rajesh has over 15 years of venture capital, corporate and entrepreneurial experience. He co-founded and served as Partner with New Markets Venture Partners (NMVP), a leading venture capital fund in the Washington DC region with over 20 portfolio companies in information technology, health care and education. Rajesh worked at NMVP across the life cycle of fund raising, investing, building companies and exiting investments. Prior to co-founding NMVP in 2002, Rajesh worked in operational roles at Godrej-GE Appliances, Career Plan and Kirloskar Electric. Rajesh is part of the Adjunct Faculty at the University of Maryland’s Executive MBA program. He is a TIE DC Charter Member and has served on committees of the U.S. National Science Foundation and the Maryland Technology Development Corporation. He holds a MBA from University of Maryland and a B.E from REC, Surathkal. <a href="mailto:rajesh@ilpimec.in">rajesh@ilpimec.in</a></td>
</tr>
<tr>
<td>Sridhar Ramanathan</td>
<td>Executive Director ReaMetrix India Pvt. Ltd., Bangalore</td>
</tr>
<tr>
<td></td>
<td>Sridhar Ramanathan is the Executive Director of ReaMetrix India Pvt. Limited. ReaMetrix is a biotechnology company focused on the development of medical diagnostic solutions from a global perspective. Sridhar is an Engineer in Instrumentation Engineering from BITS, Pilani and a PhD in Bioanalytical chemistry from the University of Kentucky. At ReaMetrix, Sridhar has led the Manufacturing operations and Product Development prior to leading operations. He is currently working on the launch of applications on ReaMetrix proprietary hardware platform, IMMEDIA. <a href="mailto:sridhar@reametrix.com">sridhar@reametrix.com</a></td>
</tr>
<tr>
<td>BV Ravi Kumar</td>
<td>Chairman and Managing Director XCyton Diagnostics Ltd., Bangalore</td>
</tr>
<tr>
<td></td>
<td>Ravi Kumar is the founder of XCyton, and functions in the capacity of Chairman and Managing Director. Dr. Ravi Kumar has been instrumental in developing all the products and has successfully launched all the products in the market. Dr. Ravi Kumar's networking abilities have created a huge extended family of collaborators for XCyton. Dr. Ravi Kumar also has been instrumental in getting venture funding, grants and soft loans from Government of India. In XCyton Dr. Ravi Kumar has guided two M.D dissertations and is currently guiding a Ph.D. Dr. Ravi Kumar was earlier with Astra Research Centre where he was the project coordinator and lead research on M. tuberculosis and Neurocysticercosis and also guided a Ph.D. Dr. Ravi Kumar has done his Ph.D in Neurochemistry from Indian Institute of Science. He trained in Psychiatry at CMC Vellore, and graduated in medicine from JIPMER, Pondicherry. <a href="mailto:ravikumar@xcyton.com">ravikumar@xcyton.com</a></td>
</tr>
<tr>
<td>Camilla Rodrigues</td>
<td>Consultant Microbiologist, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai</td>
</tr>
<tr>
<td></td>
<td>Camilla Rodrigues is a Consultant Microbiologist and the Chair of Infection Control at the Hinduja Hospital. She completed her MBBS from AFMC, in 1979, and subsequently completed her MD (Microbiology) from AFMC in 1987, and joined Hinduja in 1988. She is currently a recognized postgraduate teacher for DNB Microbiology and is a guide for Msc and PhD at the University of Mumbai. She served as a member of the Task Force, under the DGHS, GOI to assess, review and suggest measures for antibiotic resistance in 2010. She is currently a member of the National Working Group for TB on Case Finding &amp; Diagnostics for The National Strategic Plan (2012-2017), Central TB Division, and also a member of the National Laboratory Committee under the Revised National Tuberculosis Control Program. She has authored 162 publications in international and national journals, and conducted 68 research projects on TB as the principal or co-investigator. <a href="mailto:dr_crodrigues@hindujahospital.com">dr_crodrigues@hindujahospital.com</a></td>
</tr>
<tr>
<td>Gayatri Saberwal</td>
<td>Faculty Scientist Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore</td>
</tr>
<tr>
<td></td>
<td>Gayatri Saberwal did her PhD in the life sciences at the Centre for Cellular and Molecular Biology, Hyderabad. She then did post-doctoral work at the Weill Medical College of Cornell University, New York. She has been involved with the Institute of Bioinformatics and Applied Biotechnology (IBAB) since its establishment in 2001. Her research, teaching and general writing relates to the biotech industry, both in India and abroad. Dr. Saberwal is also involved in the entrepreneurship activities of IBAB, including its business incubator. She is on the Faculty Advisory Board of the National Entrepreneurship Network, a member of the HRD Task Force of the Department of Biotechnology (DBT), Govt. of India, and a member of the Pharmaceuticals’ sub-group of the Health Sector Innovation Council, a sub-group of the National Innovation Council. <a href="mailto:gayatri@ibab.ac.in">gayatri@ibab.ac.in</a></td>
</tr>
</tbody>
</table>
**Kuldeep Singh Sachdeva**  
Chief Medical Officer, RNTCP, Central TB Division, Ministry of Health & Family Welfare, New Delhi

KS Sachdeva is the Chief Medical Officer, Central TB Division, Ministry of Health and Family Welfare. He holds a MBBS degree from Maulana Azad College along with Diploma in TB and Chest Diseases from V.P. Chest Institute and an MBA in Health Care Administration from University of Delhi. Dr. Sachdeva has held several senior positions within the Ministry of Health. Prior to working with Central TB Division, Dr. Singh was the Chief Medical Officer Essential Drugs Programme, Central Procurement Agency (2004-2006), Chief Medical Officer, Department of Medicine, Lok Nayak Hospital, New Delhi (1989-2003) and also Zonal Coordinator for various Public Health Programmes for Delhi (1994-2002). In his current position as Chief Medical Officer, Dr. Singh is team leader for Programmatic Management of Drug Resistant TB, Diagnostics, Public Private Mix in TB Control and Advocacy, Communication and Social Mobilization and Health System strengthening.

**Sandeep Sen**  
Director, Sen Diagnostics (P) Ltd, Patna

Sandeep Sen M.D. is the Director of Sen Diagnostics, a private enterprise operating a large network of clinical laboratories in eastern India. Trained in Tropical Medicine, Hematology and Clinical Pathology, he monitors operations of two advanced diagnostic centers located in Patna and Cuttack. He also coordinates the Public-Private-Partnership arrangements with the state government offering subsidized diagnostic services through 22 rural labs and 210 service points. For the past two decades he has been a resource person for creating AIDS & Health Awareness among the youth, promoting Quality-Control in clinical laboratories across India, collaborating research activities and evaluating high-end diagnostic techniques appropriate for rural implementation.

**Shiladitya Sengupta**  
Director, Laboratory For Nanomedicine, Brigham and Women's Hospital, Harvard University, Boston

Shiladitya obtained his bachelors with honors and masters from the All India Institute of Medical Sciences, where he received the Geeta Mital Gold Medal. He then went to Trinity College, University of Cambridge as a British Chevening and Nehru Scholar for his PhD in pharmacology. His postdoctoral training was in biological engineering at the Massachusetts Institute of Technology. He has received the Shakuntala Amir Chand Prize from the Indian Council for Medical Research and the Young Investigator award from the American Society for Pharmacology and Experimental Therapeutics. He was recently selected for the TR35 Innovator Award by MIT-Technology Review Magazine.

**A Vijay Simha**  
Chief Strategy Officer BPL Ltd, India

Vijaya Simha was steering the Health Management Solutions team at BPL Ltd., over the last 5 years before joining the Corporate team at BPL Ltd as Chief of Corporate. He graduated from BITS Pilani in 1979 and has worked in various domains that involved semiconductor and polymer material characterization, bioprocesses, bulk drug and pharma formulation, high precision engineering and factory automation, aerospace components manufacturing and non-destructive testing and medical devices. Before moving back to India, was the CEO of Europe and Americas for Unisantis located in Geneva. He is an active associate in a number of Industry and social development organizations.

**Anand Sivaraman**  
Co-founder Remidio Innovative Solutions, Bangalore

Anand received his doctoral degree in Chemical Engineering from the Massachusetts Institute of Technology (MIT) and his Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology (IIT) Kharagpur, India. Upon returning to India in 2005, Anand worked in the areas of Instrument Design and development, Diagnostic Assay development, Product Evangelism and finally in Business Development, as part of ReaMetrix, an entrepreneurial company focused on innovations that lead to affordable diagnostics in the developing nation context. Anand is the co-founder of Remidio, a medical-devices company with the vision of using the concept of design thinking early in the product development process, to create innovative healthcare solutions that fit the constraints of the local context. Remidio’s first product is a handheld, easy-to-use fundus imaging system for retinal screening.
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Small</td>
<td>Deputy Director, TB, Global Health Program, Bill &amp; Melinda Gates Foundation, Seattle</td>
<td>Since 2002 Peter Small has served as the Team Leader for TB at the Gates Foundation. He has been responsible for developing the foundation’s TB strategy, building the programs core partnerships, hiring and managing the team and serving as the foundation’s voice for TB. Dr. Small received his medical degree from the University of Florida. He completed his post graduate training in internal medicine at UCSF and infectious diseases at Stanford. Immediately prior to joining the Gates Foundation, he was on the faculty of Stanford’s Division of Infectious Disease and Geographic Medicine. Dr. Small has published more than 150 articles including studies that helped to shape the public health response to the resurgence of TB in the USA in the 1990’s. In 2002, he was awarded the Princess Chichibu Global TB Award for his pioneering contributions to global TB control. In 2011, he moved to New Delhi, to assume a leadership role for the Foundation’s TB program in India.</td>
</tr>
<tr>
<td>Natarajan Sriram</td>
<td>Director Tulip Group, Goa</td>
<td>Natarajan Sriram, is founder Director/ Managing Partner of the Tulip Group, Goa. He graduated in science and obtained his masters degrees (MSc and M. Phil) in the field of Plant Biochemistry and later changed his focus to Immunology and human diagnostics. After acquiring basic skills and experience in manufacturing, sales and marketing of diagnostic tests while working for companies including Behring Diagnostics (now Dade-Behring), he, along with his two partners, set up their first company, Tulip Diagnostics (P) Ltd. in 1990. In the last 21 years, “Tulip Group” has grown considerably with eight group companies, and is the largest provider of Immunodiagnostic tests in India. Sriram is a panel member of Diagnostics Evaluation Experts Panel set up by the WHO, functioning as a temporary advisor to WHO. He was also a panel member of the experts committee set up by the DCGI that formulated the current national Diagnostics Guidelines.</td>
</tr>
<tr>
<td>Soumya Swaminathan</td>
<td>Scientist G, National Institute for Research in TB, Chennai</td>
<td>Soumya Swaminathan is currently Scientist G (Director Grade) at the Tuberculosis Research Centre in Chennai and leads the research program on TB/HIV. For the past two years, she served as Coordinator for Neglected Priorities Research at the Special Programme for Research and Training in Tropical Diseases (TDR), WHO, Geneva. She is also Honorary Adjunct Professor of Medicine at Tufts University, USA. She holds an MBBS degree from the AFMC, Pune, an MD in Pediatrics from AIIMS, New Delhi and was a Fellow in Pediatric Pulmonology from the Children’s Hospital of Los Angeles USA. She is a fellow of the National Academy of Medical Sciences, New Delhi and the Indian Academy of Pediatrics and serves on many national and international scientific committees. She has over 140 publications in peer-reviewed journals. Her research group is well funded with several grants from national funding agencies as well as the NIH.</td>
</tr>
<tr>
<td>Javid Syed</td>
<td>TB/HIV Project Director, Treatment Action Group, New York</td>
<td>Javid Syed is the TB/HIV Project Director at the Treatment Action Group. In this capacity, his work focuses on strengthening TB policy, speeding up research and development for tools and operational solutions to improve program scale up and treatment outcomes, and increasing the implementation of those policies and tools, especially for people with TB/HIV. Prior to his work at TAG, Javid had worked in policy advocacy and capacity building for HIV/AIDS organizations serving immigrant and people of color communities in the U.S. Javid has a Master’s degree in public health from Columbia University.</td>
</tr>
<tr>
<td>Brad Tytel</td>
<td>Vice President Global Health Strategies, New York</td>
<td>Brad Tytel is a Vice President at Global Health Strategies, which he joined in 2006. For much of his time at GHS, Brad has helped lead the consultancy’s work on TB and TB innovation, including policy, advocacy and communications projects on diagnostics, drugs and vaccines in a number of BRICS countries. He also works with GHS teams in New York and Delhi on a variety of projects in other disease areas that are exploring opportunities to engage developing countries in global health innovation more broadly. Immediately prior to joining GHS, Brad was a consultant with the Global Alliance for TB Drug Development. He holds an MA in journalism from New York University and a BA in Development Studies from Amherst College.</td>
</tr>
</tbody>
</table>
Jitendra N. Verma
Managing Director, Lifecare Innovations Pvt Ltd, New Delhi

Jitendra Verma is an Academician, Scientist and Industrialist. A PhD from PGIMER, Chandigarh he has worked at several institutions in USA. Dr Verma has over 34 years of academic and industrial research. Dr Verma has pioneered development of NDDS based Liposomal and Nano-Drugs. Dr Verma contributed to development of Asia’s first and world’s best antifungal drug FUNGISOME™ - a Liposomal Amphotericin B. Presently Dr Verma is developing Liposomal and Nano-Drugs for treatment of Tuberculosis, Cancer, Leishmaniasis and Fungal infection. He has number of publications, reviews and patents and is the recipient of numerous national and state awards and honors, including 2006-07 - Vigyan Ratna Award (Jewel of Science) from Govt. of Uttar Pradesh for contribution to Science & Technology.

jnverma@lifecareinnovations.com

K VijayRaghavan
Director, National Centre for Biological Sciences, Bangalore

K. VijayRaghavan completed both his Bachelor of Technology degree and his Master of Technology degrees in Chemical Engineering at the Indian Institute of Technology, Kanpur. He holds a Ph.D. in Molecular Biology from the Tata Institute of Fundamental Research, Mumbai. Between 1984 and 1988, he was a Research Fellow and then a Senior Research Fellow at the California Institute of Technology, Pasadena, CA, USA. He is currently Senior Professor in the area of Developmental Genetics and Director of the National Centre of Biological Sciences, Bangalore. VijayRaghavan also heads the new Institute for Stem Cell Research and Regenerative Biology (inStem) in Bangalore. His current interests lie in understanding the mechanisms underlying the formation of muscles, nerves and the development of locomotion.

vijay@ncbs.res.in

Gene Walther
Deputy Director, Diagnostics, Bill & Melinda Gates Foundation, Seattle

Gene Walther joined the Bill & Melinda Gates Foundation in 2010 as Deputy Director – Diagnostics, where he is responsible for the Foundation’s diagnostics strategy to organize and harmonize cross-Global Health Diagnostics efforts to achieve maximum impact. Before joining the foundation, Walther worked in the Venture Capital industry with Bay City Capital and as Executive Chairman for one of their investment companies, GenturaDx. Walther has over two decades of experience in the health care field. Walther joined Chiron in 2000 and held several senior leadership positions including President of Chiron’s Blood Testing Division prior to the acquisition by Novartis in 2006. Following the acquisition, he was President, Novartis Diagnostics directing global operations for an $800+ million business focused in blood testing and diagnostics. He has held senior leadership positions at Gen-Probe, Abbott Laboratories and American Hospital Supply. Mr. Walther holds a BS degree in Microbiology and Immunology from Michigan State University and a MBA from the University of Washington.

Gene.Walther@gatesfoundation.org

Paul Wilson
Consultant, Results for Development Institute & Professor, Columbia University, NY

Paul Wilson is a scientist and economist working to bring new drugs and vaccines to developing countries. Currently a consultant to NGOs and international organizations, Dr. Wilson has been Director of Policy Analysis at the International AIDS Vaccine Initiative and Associate Director of the Earth Institute at Columbia University. At Columbia, where he is on the faculty at the Mailman School of Public Health. Before moving to Columbia, he held research positions at Harvard, Rockefeller University, and Cornell Medical College, where he was Assistant Professor of Cell Biology. Dr. Wilson holds a Ph.D. in Zoology from the University of California at Berkeley, an M.Sc. degree in Economics from the London School of Economics. Dr. Wilson’s recent work focuses on vaccine financing and on development of new drugs and vaccines for developing countries. He is currently leading an analysis of India’s role in neglected disease R&D for the Results for Development Institute.

pw2101@columbia.edu

Conference co-chairs
John Kenneth, MD
Madhukar Pai, MD, PhD

Conference venue
Pope Paul VI Auditorium, St. Johns Research Institute, St. Johns National Academy of Health Sciences
John Nagar, Koramangala, Bangalore 560034